Skip to main content
. Author manuscript; available in PMC: 2020 Sep 15.
Published in final edited form as: Cancer Treat Rev. 2019 Oct 28;81:101912. doi: 10.1016/j.ctrv.2019.101912

Fig. 1. Anti-tumor mechanisms of regorafenib.

Fig. 1.

Regorafenib inhibits a broad range of activated pathways related to angiogenesis, metastasis, cell proliferation, and immunosuppression. This provides putative mechanisms for its anti-tumor efficacy in CRC.